Home

Jiangsu Hengrui Medicine Europe

PharmaBoardroom Jiangsu Hengrui Medicin

Jiangsu Hengrui Medicine Co., Ltd. engages in the manufacture and distribution of pharmaceutical and health food products. Its business activities include the development, manufacture, and distribution of raw chemical pharmaceuticals, injections, tablets, capsules, western medicines, medicine packaged materials, and raw medicines Jiangsu Hengrui Medicine is a global pharmaceutical company engaged in the research, development, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, surgical drugs, contrast agents and antibiotics. The company was established in 1970 and is headquartered in Lianyungang, Jiangsu Jiangsu Hengrui Medicine Co., Ltd. develops, manufactures, and markets a variety of medicines and medicine packing materials. The Company's products include anti-tumor medicines, pain-killers. History. Founded in 1970, Jiangsu Hengrui Medicine was originally state-owned and called Lianyungang Pharmaceutical Factory (Chinese: 连云港制药厂).Headquartered in Lianyungang, Jiangsu, it was established in its current form in 1977.The company was listed on the Shanghai Stock Exchange in 2000 and now has locations in China, the United States, Germany, Switzerland, Japan, and Australia The European hub for clinical research and development will help the company to advance its innovative drugs, including cancer treatments. The Basel life sciences ecosystem is set to grow by another major global player. The international company Hengrui Medicine is establishing a Swiss subsidiary, Hengrui Europe Therapeutics AG

Jiangsu Hengrui Medicine Company Limited, also known as Jiangsu Hengrui Medicine, is a Chinese pharmaceutical company which engaged in the research, development, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a leading biopharmaceutical company based in China with annual net sales of over $1.6 billion in 2016. Hengrui is devoted to empowering healthier lives through research,. The Basel life sciences ecosystem is set to grow by another major global player. The international company Hengrui Medicine is establishing a Swiss subsidiary, Hengrui Europe Therapeutics AG. Founded in 1970, the Chinese company reportedly has a market capitalization of about $70 billion and therefore ranks as one of the top 30 life sciences companies in the world Sandrine Gioria | Basel, Basel, Schweiz | Director Clinical Operations chez Jiangsu Hengrui Pharmaceuticals Co.,Ltd. | Clinical Operations Professional with over 20+ years experience in clinical research as Clinical Research Associate, Clinical Trial Manager, Process and Compliance Manager, Project Manager, Head Clinical Pharmacology Operations., and Director Clinical Operations About Hengrui: Hengrui is the biggest Chinese pharma company with 25'000 employees, headquartered in Shanghai. With strong research focus in oncology, diabetes and metabolic diseases, autoimmune diseases, HIV, we have just started transforming into a global player. In 2020, we started establishing our entities in Europe and USA

Sun Piaoyang is stepping down as Jiangsu Hengrui Medicine's chairman after a 30-year run. (Getty/Robert Daly) In a surprising move, the richest man in China's biopharma industry is stepping down According to Jiangsu Hengrui Medicine's financial reports the company's revenue in 2020 were 27.73B an increase( +17.39%) over the years 2019 revenue that were of 23.29B. In 2020 the company's total earnings were 6.33B while total earnings in 2019 were 5.33B( +20%). Company's stock symbol is 600276.SS. Lastest price : 83.25

Anna Janaś | Warszawa, Woj. Mazowieckie, Polska | Senior Director of Clinical Operations/Europe w Jiangsu Hengrui Medicine Co., Ltd. | 15 years of experience in effective management and monitoring of the multiple projects (including preventive and therapeutic vaccines, oncology, immunoinflamation, respiratory, urology and cardiology studies) in two pharmaceutical companies Pfizer and GSK. Jiangsu Hengrui Medicine Co., Ltd.// Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is the largest research and manufacturing base of antineoplastics and surgical medicine in China. Hengrui Group consists of four parts, the headquarter is located in Lianyungang, Jiangsu Province, another three R&D centers andproduction basesare respectively located in Shanghai, Chengdu and New Jersey

Jiangsu Hengrui Medicine's SHR-1020 (famitinib) for bile duct cancer saw its Phase Transition Success Rate (PTSR) tank nine points to 25% after withdrawing its Phase II. The PTSR score change occurred on 23 June after ClinicalTrials.gov updated the trial from not yet recruiting to withdrawn on 16 June. PTSR is the probability. China. Hengrui Medicine is one of the top 30 life sciences companies in the world. In China, where Hengrui was founded, it is the largest pharmaceutical company by market value by May 2021. In 2020, Hengrui opened its Swiss subsidiary in Basel. The site will be dedicated to the clinical research and development of innovative drugs in Europe

JIANGSU HENGRUI MEDICINE CO., LTD. : Trading strategies, financial analysis, commentaries and investment guidance for JIANGSU HENGRUI MEDICINE CO., LTD. Stock.

About - Hengrui Us

  1. Jiangsu Hengrui Pharmaceuticals Co., Ltd. | 16,414 followers on LinkedIn. Scientific research oriented, creating a healthy life! | Hengrui Medicine is a leading pharmaceutical company based in.
  2. Market capitalization of Jiangsu Hengrui Medicine (600276.SS) Market cap: $62.25 Billion As of July 2021 Jiangsu Hengrui Medicine has a market cap of $62.25 Billion.This makes Jiangsu Hengrui Medicine the world's 281th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's.
  3. Grade: pharmaceutical grade. Factory Location: Lianyungang, Jiangsu, China Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Asia,Middle East,Africa Sample Provided: no Desflurane is a highly fluorinated methyl ethyl ether used for maintenance of general anesthesia
  4. JIANGSU HENGRUI MEDICINE CO., LTD. : Forcasts, revenue, earnings, analysts expectations, ratios for JIANGSU HENGRUI MEDICINE CO., LTD. Stock | 600276 | CNE0000014W
  5. INCYTE EUROPE SARL. AND. JIANGSU HEnGRUI MEDICINE CO., LTD. SEPTEMBER 1, 2015 [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission. CONFIDENTIAL TREATMENT MATERIAL . TABLE OF CONTENTS.
  6. On Monday, Jiangsu Hengrui Medicine Co Ltd (600276:SHH) closed at 60.96, 4.42% above its 52-week low of 58.38, set on Jul 15, 2021

Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a leading biopharmaceutical company based in China with annual net sales of over $2.2 billion in 2017. Hengrui is devoted to empowering healthier lives through research, with a team of over 20,000 employees in China, the United States, Australia, Japan and Germany Jiangsu Hengrui Pharmaceutical Co., Ltd. is a medical and health enterprise engaged in medical innovation and high-quality drug R&D, production, and promotion. It was listed on the Shanghai Stock Exchange in 2000. Hengrui is a well-known supply of anti-tumor drugs, surgical drugs, and contrast agents in China Manufacturer: Jiangsu Hengrui Medicine Co., Ltd. Address: No.22, Jinqiao Road, Dapu Industrial Park, Lianyungang, Jiangsu, China E-mail: dongwei @hrs.com.cn Telephone: +86-518-85159923 Fax: +86-518-85465746 1.4 Emergency telephone number +86-518-85473511 SECTION 2: Hazards identification.

China's Jiangsu Hengrui Medicine signed a deal with U.S.-based Incyte that could be worth as much as $795 million with milestones to outlicense rights outside of Greater China for its clinical. 0709 trax. BioCentury & Getty Images. Jiangsu Hengrui chairman steps down; plus Ovid, Verrica and Elevar. By BioCentury Staff. Read the full 195 word article. This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other. Jiangsu Hengrui Medicine Co., Ltd. established in 1970, is a leading biopharmaceutical company based in China with annual net sales of about USD 2.5 billion in 2018. Hengrui has more than 140 clinical trials ongoing worldwide and an in-house sales force covering more than 18,000 hospitals in China Sidley Austin LLP advised Jiangsu Hengrui Medicine Co., Ltd. in entering into a license agreement with CrystalGenomics, Inc. Crystal Genomics (KOSDAQ: 083790), a South Korea-based biopharmaceutical company, announced it had signed an agreement of exclusive licensing in Korea for Camrelizumab, an immune checkpoint inhibitor of the PD-1 antibody, with Jiangsu Hengrui Medicine (SHA: 600276), a.

Jiangsu Hengrui Medicine Co Ltd - Company Profile and News

  1. Tokyo-based Oncolys BioPharma has agreed to license China rights to its oncolytic virus candidate, OBP-301, to Jiangsu Hengrui Medicine for a therapy area that saw a first-in-class approval for.
  2. Her husband worked his way up from technician at Lianyungang Pharmaceutical, a state-run chemical factory, eventually leading the company to develop anti-tumour drugs in the 1990s and changing its name to Jiangsu Hengrui Medicine Company. The two companies have benefited handsomely from China's rapidly growing pharmaceutical industry
  3. Jiangsu Hengrui Medicine has 200,000 employees at their 1 location. See insights on Jiangsu Hengrui Medicine including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft

Jiangsu Hengrui Medicine - Wikipedi

  1. About Jiangsu Hengrui Medicine Co., Ltd. Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical company, headquartered in China, with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, Hengrui has 6 new molecular entities approved in China as well as 30 plus programs in.
  2. 10 Dec 2020 Jiangsu HengRui Medicine plans a phase II trial in Type 2 diabetes (Treatment-experienced) (SC, Injection) in January 2021 (NCT04663282) Subscriber content You need to be a logged in subscriber to view this content
  3. Jiangsu Hengrui Medicine Co., Ltd., established in 1970, having over 13,000 employees globally, is the largest manufacturer of antineoplastics in China. Its operating income was over USD 1.7 billion in 2015. The company stock was officially listed on the Shanghai Stock Exchange in 2000. All APIs and finish dosage forms have passed nationa
  4. 600276 | Complete Jiangsu Hengrui Medicine Co. Ltd. A stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview
  5. Jiangsu Hengrui Medicine Co., Ltd., established in 1970, having over 17,000 employees globally, is the largest manufacturer of antineoplastic drgus, surgical drugs and contrast media in China. Its operating income was over USD 2.4 billion in 2017. The company stock was officially listed on the Shanghai Stock Exchange in 2000
  6. We use cookies for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used
  7. I think HLB(028300: KOSDAQ) in Korean market is better, which has bigger apatinib global market except China, and it's market capital is about 1/10 of Hengrui Medicine. Reply 1

EBITDA Interim CAGR (5Y) 21.17. Free Operating Cash Flow CAGR (5Y) 1.43. Total Debt CAGR (5Y) 76.05. Net Profit Margin Growth Rate (5Y) -0.96 Top key players @ AstraZeneca, Laekna, Novartis, Jiangsu HengRui Medicine, Roche, Olema Pharmaceuticals, Haihe Biopharma, G1 Therapeutics, Merck, and Chia Tai Tianqing Pharmaceutical The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of HR.

Hengrui Medicine Sets Up Clinical Research and Development

Press release - Decisive Markets Insights - INHALATION ANESTHESIA Market Top Key Players- Jiangsu Hengrui Medicine Co., Ltd., Lunan Pharmaceutical Group Co. Ltd, Novartis AG, Piramal Enterprises. Jiangsu Hengrui Medicine Co. Ltd. A company facts, information and financial ratios from MarketWatch

Jiangsu Hengrui Medicine Co. Ltd. A balance sheet, income statement, cash flow, earnings & estimates, ratio and margins. View 600276.CN financial statements in full View the latest Jiangsu Hengrui Medicine Co. Ltd. A (600276) stock price, news, historical charts, analyst ratings and financial information from WSJ Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a leading biopharmaceutical company based in China with annual net sales of over $2.57 billion in 2018. Hengrui is devoted to empowering healthier lives through research, with a team of over 21,000 employees in China, the United States, Australia, Japan and Germany 12/22. NCT02824458: A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations. [VIRTUAL] ACTIVE: Apatinib plus gefitinib versus placebo plus gefitinib as first-line treatment for advanced epidermal growth factor receptor-mutant (EGFRm) non-small-cell lung cancer. Jiangsu Hengrui Pharmaceuticals Co.LTD | 15,806 followers on LinkedIn. Scientific research oriented, creating a healthy life! | Hengrui Medicine is a leading pharmaceutical company based in China.

4 Jiangsu Hengrui Medicine reviews. A free inside look at company reviews and salaries posted anonymously by employees Incyte to pay Hengrui $25 million upfront plus the potential for milestone and royalty payments Sep. 2, 2015- Incyte Corporation (Nasdaq: INCY) today announced a global license and collaboration agreement with Jiangsu Hengrui Medicine Co., Ltd. for the development and commercialization of SHR-1210, an investigational anti-PD-1 monoclonal antibody Management tracks: Sun departs as Hengrui chair; plus Blackstone, Ipsen, bluebird, BioNTech, Catalent, Foundation, Twist, Lantheus, Abcam and more. Jiangsu Hengrui Medicine Co Ltd. (Shanghai:600276) said Piaoyang Sun will step down as chairman. Sun, who has led the company for 30 years, will continue to serve on the board's strategy committee. Jiangsu Hengrui Medicine Co., Ltd. established in 1970, is a leading biopharmaceutical company based in China with annual net sales of over $2.5 billion in 2018 Inventory Turnover measures how fast the company turns over its inventory within a year. It is calculated as Cost of Goods Sold divided by Total Inventories.Jiangsu Hengrui Pharmaceuticals Co's Cost of Goods Sold for the three months ended in Mar. 2021 was CN¥910 Mil.Jiangsu Hengrui Pharmaceuticals Co's Total Inventories for the quarter that ended in Mar. 2021 was CN¥1,910 Mil

Jiangsu Hengrui Medicine's $87

Get Jiangsu Hengrui Medicine Co Ltd (276-SZ:Shanghai Stock Exchange) real-time stock quotes, news, price and financial information from CNBC 1 Day 600276 -0.32% DJIA 1.62% S&P 500 1.52% Health Care/Life Sciences 0.64% Wei Dong Chairman-Supervisory Board Jiangsu Hengrui Medicine Co., Ltd., Lianyungang Hengchuang Medical Technology Co. Jiangsu Hengrui Medicine Announce Collaboration with Albert Einstein College of Medicine to Advance Cancer Research and Drug Discovery LIANYUNGANG, China, April 25, 2016 /PRNewswire/ -- Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) an..

Jiangsu Hengrui Medicine on the Forbes Growth Champions List

600276:SHH Shanghai Stock Exchange. Jiangsu Hengrui Medicine Co Ltd. Actions. Add to watchlist. Add to portfolio. Add an alert. Health Care Pharmaceuticals & Biotechnology. Price (CNY) 84.11. Today's Change 1.13 / 1.36% Jiangsu Hengrui Pharmaceuticals Co Ltd is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs and anti-infection medications Published by Lai Lin Thomala , May 21, 2021. In 2020, the Chinese firm Jiangsu Hengrui Medicine generated a total revenue of 27.7 billion yuan, indicating a steady growth over the past few years.

TG Therapeutics and Jiangsu Hengrui Medicine Announce

Feb 8 (R) - Jiangsu Hengrui Medicine Co Ltd : * The company will be able to manufacture and sell its injection in the United States after receiving the FDA approval Source text in Chinese. A brief financial summary of Jiangsu Hengrui Medicine Co Ltd as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from.

Hengrui Medicine sets up clinical research and development

Interactive Chart for JIANGSU HENGRUI MEDICAL CO LTD (600276.SS), analyze all the data with a huge range of indicators How has Jiangsu Hengrui Medicine's share price performed over time and what events caused price changes? Latest Share Price and Events. Stable Share Price: 600276 is not significantly more volatile than the rest of CN stocks over the past 3 months, typically moving +/- 4% a week Oral Electrolytes Market is projected to reach USD 18.34 Billion by 2028: Sanofi S.A., Halewood Laboratories Pvt. Ltd., Abbott Laboratories, Mead Johnson, Jiangsu Hengrui Medicine rc April 14, 2021 Home/Business/ Raloxifene Hydrochloride Market Size, Industry Trends and Forecast to 2028 | Major Players - Eli Lilly and Company, InvaGen Pharmaceuticals Inc, Actavis, Camber Pharmaceuticals Inc., Jiangsu Hengrui Medicine Co. Ltd., Teva Pharmaceutical Industries Ltd 600276.CN Company Profile & Executives - Jiangsu Hengrui Medicine Co. Ltd. A - Wall Street Journal. News Corp is a global, diversified media and information services company focused on creating.

Sandrine Gioria - Director Clinical Operations, Europe

Annual and quarterly financial reports, income statements and balance sheets for JIANGSU HENGRUI MEDICINE CO.,LTD. (600276) on MSN Money Jiangsu Hengrui Medicine, one of China's largest non-government-controlled pharmaceutical manufacturers, said today it won final approval from the U.S. Food and Drug Administration for the sale. Jiangsu Hengrui, Chinese Cancer Drugmaker Emerging from the Shadows. A flagship in the Chinese oncology market, Jiangsu Hengrui Medicine (600276:SH) was accused of corruption in sales. This was soon followed by good news - an approval of a Phase III clinical test. Will a bright future erase the black stain

This website uses cookies. Analytical cookies help us improve our website by providing insight on how visitors interact with our site, and necessary cookies which the website needs to function properly Very easy. Easy. Moderate. Difficult. Very difficult. Thanks for your vote! Pronunciation of JIANGSU HENGRUI with 1 audio pronunciations. 0 rating Jiangsu Hengrui Medicine. Over the past year, Hengrui, China's largest pharma company, has received half-a-dozen approvals from the FDA, giving global sales at the generic- and innovative-drugs. Main companies covered in this report:: Jiangsu Hengrui Medicine, GE Healthcare, Aposense, Guerbet Group, Eli Lilly, Alseres Pharmaceuticals, Spago Nanomedical, The report studies the status and outlook of different regional markets such as Europe, North America, the MEA, Asia Pacific, and South America. All of the regional markets. The organizational chart of Jiangsu Hengrui Medicine displays its 30 main executives including Yunshu Zhou, Song Zhou and Scott Filosi × We use cookies to provide a better service. By continuing your navigation, you consent to their use

Jiangsu Hengrui Medicine Co

Jiangsu Hengrui Pharmaceuticals Co

Jiangsu Hengrui Me. stock price, live market quote, shares value, historical data, intraday chart, earnings per share and news Jiangsu Hengrui Medicine develops, manufactures, and markets a variety of medicines and medical packing materials. The Company's products include anti-tumor medicines, painkillers, anti-infection medicines, aluminum foil, and other related products. Taking the slogan that Science & Technology for a Better Life, Hengrui Medicine i China approves Hengrui breast cancer drug on Phase II data. Jiangsu Hengrui Medicine Co. Ltd. (Shanghai:600276) said China's State Drug Administration conditionally approved pyrotinib in combination with capecitabine to treat HER2-positive, advanced or metastatic breast cancer

Hengrui's Sun Piaoyang, China's richest pharma leader

LSK BioPharma and Jiangsu Hengrui Medicine announced that the companies have entered into a global clinical collaboration in patients with advanced hepatocellular carcinoma (HCC), evaluating the safety and efficacy of LSKB's rivoceranib, also known as apatinib or Aitan® (brand name) in China, a selective and potent VEGFR-2 inhibitor, in combination with Hengrui's camrelizumab (SHR-1210. Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical company, headquartered in China, with 24,700 employees devoted to empowering healthier lives through research. With over $3.3. There are currently no open jobs at Jiangsu Hengrui Medicine listed on Glassdoor. Sign up to get notified as soon as new Jiangsu Hengrui Medicine jobs are posted

Jiangsu Hengrui Medicine Co., Ltd., established in 1970, is a leading biopharmaceutical company based in China with annual net sales of over $1.6 billion in 2016. Hengrui is devoted to empowering. Jiangsu Hengrui Medicine Co., Ltd. is a global biopharmaceutical company, headquartered in China, with 24,700 employees devoted to empowering healthier lives through research. With over $3.3 billion in revenue in 2019, Hengrui has 6 new molecular entities approved in China as well as 30 plus programs in clinical development in China, US, EU and. 15 May 2020 Jiangsu HengRui Medicine plans a phase II/III trial for preoperative sedation (Intranasal) in May 2020 (NCT04383418) 03 Feb 2020 Jiangsu Hengrui Medicine initiates enrolment in a phase I trial (In volunteers) in China (ChiCTR1900026141) Subscriber content You need to be a logged in subscriber to view this content.. b. Arcutis has paid Forty Thousand Dollars ($40,000) of withholding taxes to the U.S. Department of Treasury Internal Revenue Service on Hengrui's behalf in addition to and in respect of the Upfront Payment paid to Hengrui on January 30, 2018, and is required to withhold One Hundred and Fifty Thousand Dollars ($150,000) of withholding taxes on Hengrui's behalf for the Option Exercise.

Jiangsu Hengrui Medicine Brand Ranking | All Brand

Novaliq and Jiangsu Hengrui Medicine, a biopharmaceutical company based in China, announced the closing of an exclusive license agreement to develop, manufacture and commercialize water-free drugs NOV03 and CyclASol for the treatment of dry eye disease in the People's Republic of China (including mainland China, Hong Kong, Macau and Taiwan) Jiangsu Hengrui Medicine Co., Ltd. established in 1970, is a leading biopharmaceutical company based in China with annual net sales of about $2.5 billion in 2018. Hengrui is devoted to empowering healthier lives through research, with capabilities across oncology, immunology, anesthesiology, cardiovascular diseases, metabolic diseases, and pain.

Durham's Mycovia Pharmaceuticals and Jiangsu Hengrui Medicine of China have announced a collaboration to develop and commercialize Mycovia's drug candidate for treating recurrent yeast infections in women.. The drug, VT-1161, is an oral treatment for recurrent vulvovaginal candidiasis (RVVC) and onychomycosis for nail fungus. It has received Qualified Infectious Disease Product and Fast. Find Jiangsu Hengrui Medicine Co Ltd earnings date, reports, revenues and financial reports for Jiangsu Hengrui Medicine Co Ltd (600276). Latest Release Apr 20, 202 Hengrui Therapeutics, the US subsidiary of Chinese drug firm Jiangsu Hengrui Medicine, is developing the irreversible pan-HER2 tyrosine kinase inhibitor pyrotinib as a treatment for advanced non-small cell lung cancer patients with HER2 mutations Get in touch with Hui Sun from Jiangsu Hengrui Medicine Co. - direct company email address and phone number. Reach the person you're looking for and other professionals in the same industry. We use cookies in order to provide you with a better browsing experience. By continuing to use this website you agree to our use of cookies

항서제약(恒瑞医药, Jiangsu Hengrui Medicine Co

Jiangsu Hengrui Medicine Company Ltd. (Chinese: 江苏恒瑞医药股份有限公司), also known as Jiangsu Hengrui Medicine (Chinese: 恒瑞医药), is a Chinese. Get in touch with Jessie Zou from Jiangsu Hengrui Medicine Co. - direct company email address and phone number. Reach the person you're looking for and other professionals in the same industry. We use cookies in order to provide you with a better browsing experience. By continuing to use this website you agree to our use of cookies Jiangsu Hengrui Medicine Co. Mallinckrodt Pharmaceuticals All the players running in the global Ioversol market are elaborated thoroughly in the Ioversol market report on the basis of proprietary technologies, distribution channels, industrial penetration, manufacturing processes, and revenue Jiangsu Hengrui Medicine Company Ltd., also known as Jiangsu Hengrui Medicine, is a Chinese pharmaceutical company that manufactures and distributes various types of drug packaging materials. 600276.CN | Jiangsu Hengrui Medicine Co. Ltd. A Annual Balance Sheet - WSJ. Dow Jones, a News Corp company. About WSJ. News Corp is a global, diversified media and information services company. Jiangsu Hengrui Medicine Co., Ltd. engages in the research, development, manufacture, and sale of drugs. It specializes in antineoplastic agents, surgical anesthesia drugs, features infusion, contrast agents, and cardiovascular drugs. Its products include tablets, oral solution, and suspension of antineoplastic drugs and narcotic drugs; p